Santen Buys Asia, Europe Rights To Merck's Eye Drugs For $600 Million
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.
Santen Pharmaceutical has licensed eye drugs from Merck for $600 million upfront, plus milestone payments and royalties, to market them in the Asia Pacific region and in Europe.